New Transformative Obesity Treatments ? Obesity, affecting about 70% of adults in the U.S. and over half in Europe, has long been a complex issue, marred by stigma and severe health risks. However, 2023 marks a significant turning point.
A novel category of drugs, mimicking glucagon-like peptide-1 (GLP-1), has emerged, offering hope in battling obesity and related chronic diseases. These drugs were initially developed for diabetes and have shown impressive results in weight loss with manageable side effects. Recent clinical trials have demonstrated that GLP-1 drugs not only aid in weight loss but also significantly reduce the risk of heart attacks, strokes, and symptoms of heart failure. This multifaceted impact earned them the title of "Breakthrough of the Year" by Science.
Drugs like Semaglutide (Novo Nordisk) have gained immense popularity, evidenced by soaring market values and widespread use. They have even penetrated popular culture, becoming topics at events like the Academy Awards.
But as often, despite their success, these drugs come with side effects, such as gastrointestinal issues and potential risks of intestinal obstruction. There's also concern about their use by individuals who are not overweight and just want to loose a bit of weight. Looking ahead, the development of even more effective multi-hormone therapies is underway. These advancements are reshaping the understanding of obesity as a chronic biological illness, not just a lack of willpower.
read full text here:
Commenti